Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes

NEXT STORY
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
PREV STORY
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

author_avatar
NASDAQ Market News

Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

author_avatar
NASDAQ Market News

resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older

resTORbio’s TORC1 inhibitors enhanced the function of the aging immune system and were associated ...

author_avatar
NASDAQ Market News